Introduction:
A study from the Institute of Metabolic Physiology, Heinrich Heine University, Düsseldorf, Germany shows that: “Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment.” This study was published in the 16 March 2015 issue of the Journal “Nature Medicine” (one of the best journal in “General Medicine” with
an impact factor of 30+ ) by Prof. Lammert E, Marquard J and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product therapy for Diabetes mellitus: Isorhapontigenin, isolated from Aiphanes Aculeata, Norway/Sitka/White Spruce, among others, increases islet insulin levels, islet cell mass and glucose tolerance via down-regulation of NMDA receptor GluN2A
Significance:
Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) the life-long painful injection/drug treatment is required to treat DM; (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult β-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, diabetes.
What they say:
Prof. Lammert ’s research team has shown earlier that NMDAR antagonist dextromethorphan promotes glucose tolerance, suggesting that inhibition of NMDAR activity may promote glucose tolerance.
What we say:
This study suggests a Natural product-based therapy for diabetes mellitus.
I had shown earlier that Isorhapontigenin may:(1) prolong mammalian life span via down-regulation of angiotensin II type I receptor and p70 S6 Kinase and up-regulation of BuBR1; (2) promote reprogramming of adult pancreatic ductal cells into α, δ, and β cells via up-regulation of Ngn3; and (3) and inhibit the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3.
Isorhapontigenin, by increasing the expression of its target gene, it may: (1) decrease the expression of one of the subunits of NMDA receptor GluN2A; (2) increase islet insulin levels; (3) increase islet cell mass; and (4) improve glucose tolerance.
Thus, pharmacological formulations encompassing “Isorhapontigenin or its analogs“ may be used in the treatment of T2DM.
Isorhapontigenin, isolated from Aiphanes Aculeata, Norway/Sitka/White Spruce , among others, promotes insulin sensitivity and glucose tolerance via down-regulation of NMDA receptor, GluN2A
Isorhapontigenin
Norway Spruce
Sitka spruce.
White spruce (Picea glauca)
Therapeutic opportunity:
Given that Natural product Isorhapontigenin has a number of favorable pharmacological health benefits, as discussed above, to human health, it may be a drug candidate of choice to treat T2DM. Thus, pharmacological formulations encompassing “Isorhapontigenin or its analogs” may be used to increase insulin levels, islet cell mass and glucose tolerance.
# Research cooperation
Citation: Boominathan, L., Natural product therapy for Diabetes mellitus: Isorhapontigenin, isolated from Aiphanes Aculeata, Norway/Sitka/White Spruce, among others, increases islet insulin levels, islet cell mass and glucose tolerance via down-regulation of NMDA receptor GluN2A, 30/October/2016, 6.02 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
Web: http://genomediscovery.org
Idea Proposed (with factual evidence) by: Dr L Boominathan Ph.D.
Amount: $300
Undisclosed information: How Isorhapontigenin decreases the expression of NMDA receptor GluN2A and promotes insulin sensitivity
Results guaranteed if not refunded